# Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

> **NCT02609984** · PHASE2 · TERMINATED · sponsor: **Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 89 (actual)

## Conditions studied

- Sarcoma
- Myxoid/Round Cell Liposarcoma
- Synovial Sarcoma
- Metastatic Sarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Locally Advanced Sarcoma
- Liposarcoma

## Interventions

- **BIOLOGICAL:** CMB305
- **BIOLOGICAL:** atezolizumab

## Key facts

- **NCT ID:** NCT02609984
- **Lead sponsor:** Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-29
- **Primary completion:** 2019-02-06
- **Final completion:** 2019-02-06
- **Target enrollment:** 89 (ACTUAL)
- **Why stopped:** This study did not meet the efficacy objective
- **Last updated:** 2020-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02609984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02609984, "Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02609984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*